Prostate SABR With Intra-Prostatic SABR Boost
About this study
Stereotactic Ablative Radiation (SABR/SBRT) will be prescribed to a dose of 35 Gy in 5 fractions, once weekly to prostate with a simultaneous intra-prostatic boost to the MR detected nodule up to 50Gy. The pelvic lymph nodes and seminal vesicles will also receive 25 Gy in 5 weekly fractions.
- Condition
- Prostate Cancer
- Tested
- Pelvic SABR with intra-prostatic SABR
- Sponsor
- King Saud University
Who can join
- Age
- 18 to 99 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 99 years
- Eligible sex: Male
- Study condition: Prostate Cancer
- Histologically confirmed prostate adenocarcinoma
- High-risk prostate cancer, defined as at least one of: T3, Gleason 8-10, OR PSA \> 20 ng/mL
- Willing to give informed consent to participate in this clinical trial
Exclusion 5
- Prior pelvic radiotherapy
- Contraindication to radical prostate radiotherapy e.g. connective tissue disease or inflammatory bowel disease
- Contraindication to prostate MRI
- No evidence of castrate resistance (defined as PSA \< 3 ng/ml while testosterone is \< 0.7nmol/l. Patients could have been on combined androgen blockade but are excluded if this was started due to PSA progression.
- Definitive extrapelvic nodal or distant metastatic disease on staging investigations.
Where
1 site, 1 recruiting
King Saud University Medical City
Riyadh, Saudi Arabia
Contact
-
Yasir Alayed, MD
+966114671546 yalayed@ksu.edu.sa
Potential match only. Final eligibility is determined by the study team.